BIVV

Bioverativ’s Takeout, Visa’s Surge, and General Electric’s Pain

by

From Bioverativ’s takeout to Visa’s stock price surge to General Electric’s continued pain, there’s a lot going on in the stock market. Let’s cover some ground. By Kris Rosemann and Brian Nelson, CFA It’s hard to believe this but our best idea in the Best Ideas Newsletter portfolio, Visa (V), is now a $124+ per share stock. We know how to pick ‘em, would you say? We don’t get everything correct, of course, but if you’ve read anything on our website, we can only hope that you’ve witnessed Visa’s meteoric rise. The high end of our updated fair value estimate range for Visa is north of $130 per share. What a wild ride it has been, to say the least, … Read more

Roche’s Hemlibra Looks Very Promising

by

Image shown: Roche’s shares caught some relief recently. We’re big fans of clinical data reads. Thus far in 2017, we’ve posted updates on Roche (RHHBY), Shire Plc (SHPG) and Bioverativ (BIVV)–each with extensive aspirations in the field of hemophilia. In light of recent developments, a follow-up only seems appropriate as Roche’s Hemlibra is poised to disrupt the marketplace. By Alexander J. Poulos Hemophilia Overview Hemophilia is a genetic disorder that negatively affects the patient’s ability to clot when bleeding. Unlike other traditional genetic disorders, inheriting a defective gene is not the only cause of Hemophilia. According to the National Hemophilia Foundation, nearly one third of all cases are spontaneous, where neither parent is a carrier of the Hemophilia gene. Hemophilia … Read more

Shire Plc Continues To Underwhelm

by

Image Shown: Shire’s equity has been under enormous pressure as of late. The share price of Shire Plc remains under pressure after posting decent quarterly results in early August. On the surface, the results themselves do not merit the equity hitting a new low, in our view. However, the market continues to grapple with the future direction of the company. Let’s examine the various components of Shire’s underlying business in this article. By Alexander J. Poulos Overview Shire PLC (SHPG) is a Dublin, Ireland based pharmaceutical company with an interesting past. Abbvie (ABBV) attempted to acquire Shire in order to enact a tax inversion which it subsequently abandoned. The failed merger emboldened Shire to become aggressive in the M&A front … Read more

Bioverativ: A Profitable Rare Drug Company

by

The biotech sector remains one of the most innovative segments of the overall market. Cutting-edge research is being conducted to help treat a wide swath of disease states with the potential for outsize rewards if the novel treatment is proven effective. The boom-bust nature of clinical research has lead to numerous spectacular flameouts, which lessen the appeal of the sector to the more risk-averse investor. We have identified a promising newly-formed company with real earnings, and one that may be poised to accelerate earnings now that a promising new rare-disease molecule has been brought into the fold. By Alexander J Poulos Overview of Bioverativ Biovertaiv (BIVV) is a newly-formed entity that was spun off from Biogen (BIIB) in early 2017. … Read more

Analyzing the S&P SPDR Biotech ETF

by

ETFs are rapidly becoming the preferred investment vehicle to gain broad exposure to a particular sector. The biotech industry is no different with two distinct ETFs dominating the niche. The article discusses the unique characteristics of the SPDR Biotech ETF to determine the merits of the idea. By Alexander J. Poulos Introducing the S&P Spider Biotech ETF The SPDR S&P Biotech ETF (XBI) is a position weighted index with the top 10 components accounting for less than 25% of the overall assets of the index (see image below). The XBI differs sharply from its primary rival the iShares Nasdaq Biotech Index ETF (IBB) which is market-cap weighted with industry stalwarts such as Amgen (AMGN) accounting for over 8% of the … Read more